

## RESEARCH COMMUNICATION

# Cas9 function and host genome sampling in Type II-A CRISPR–Cas adaptation

Yunzhou Wei,<sup>1</sup> Rebecca M. Terns,<sup>1</sup>  
and Michael P. Terns<sup>1,2,3</sup>

<sup>1</sup>Department of Biochemistry and Molecular Biology,

<sup>2</sup>Department of Genetics, <sup>3</sup>Department of Microbiology,  
University of Georgia, Athens, Georgia 30602, USA

**To acquire the ability to recognize and destroy virus and plasmid invaders, prokaryotic CRISPR–Cas systems capture fragments of DNA within the host CRISPR locus. Our results indicate that the process of adaptation by a Type II-A CRISPR–Cas system in *Streptococcus thermophilus* requires Cas1, Cas2, and Csn2. Surprisingly, we found that Cas9, previously identified as the nuclease responsible for ultimate invader destruction, is also essential for adaptation. Cas9 nuclease activity is dispensable for adaptation. In addition, our studies revealed extensive, unbiased acquisition of the self-targeting host genome sequence by the CRISPR–Cas system that is masked in the presence of active target destruction.**

Supplemental material is available for this article.

Received December 17, 2014; revised version accepted  
January 15, 2015.

CRISPR–Cas systems provide prokaryotes with adaptive immunity against invaders such as viruses/phages and plasmids (Terns and Terns 2011; Barrangou and Marraffini 2014; Heler et al. 2014; van der Oost et al. 2014). CRISPR–Cas systems target invaders using information stored in CRISPRs: loci that contain alternating units of an identical repeat (repeats) and short invader-derived sequences (spacers) (Fig. 1A). CRISPR transcripts are processed to a battery of CRISPR RNAs (crRNAs) that each contains a unique invader guide sequence (and common repeat sequence). The crRNAs associate with Cas proteins to form effector complexes that recognize and degrade invading nucleic acids to effect immunity (Terns and Terns 2011; Barrangou and Marraffini 2014; Heler et al. 2014; van der Oost et al. 2014). Diverse CRISPR–Cas systems are prevalent in bacteria and archaea and are categorized into three compositionally distinct groups (Types I–III), with multiple subtypes within each group (Haft et al. 2005; Makarova et al. 2011).

The initial step of capturing short fragments of invasive DNA into CRISPR loci (“adaptation” or “spacer acquisition”) is the least understood aspect of the CRISPR immune pathway. Adaptation appears to be a rare event


but generates subpopulations of organisms that can survive infection. It has been proposed that the mechanism involves identification of “foreign” sequences for incorporation into the CRISPR (Datsenko et al. 2012; Yosef et al. 2012; Diez-Villasenor et al. 2013; Nunez et al. 2014), although host genome sequences have also been observed in CRISPRs at very low frequencies (Stern et al. 2010; Jiang et al. 2013; Paez-Espino et al. 2013). Selection of invader DNA fragments (protospacers) by the adaptation machinery requires the presence of a short (3- to 7-base-pair [bp]) neighboring motif called a protospacer-adjacent motif (PAM) (Mojica et al. 2009; Shah et al. 2013; Heler et al. 2014). Incorporation of each new spacer into a CRISPR locus is also accompanied by generation of a new repeat and occurs predominantly at the leader/repeat junction (Barrangou et al. 2007; Deveau et al. 2008; Garneau et al. 2010; Datsenko et al. 2012; Erdmann and Garrett 2012; Swarts et al. 2012; Yosef et al. 2012; Diez-Villasenor et al. 2013; Li et al. 2014).

An important goal toward understanding CRISPR adaptation is identifying the proteins (Cas and non-Cas) responsible for novel spacer acquisition in CRISPR loci in diverse CRISPR–Cas systems. Genetic studies indicate that overexpression of Cas1 and Cas2—the only Cas proteins universal to all CRISPR–Cas systems—is sufficient to induce adaptation in the absence of other Cas proteins in Type I systems such as that found in *Escherichia coli* (Datsenko et al. 2012; Yosef et al. 2012; Diez-Villasenor et al. 2013; Nunez et al. 2014).

Limited information is available regarding the *trans*-acting factors required for adaptation in Type II CRISPR–Cas systems (and no work has yet been done regarding adaptation in Type III systems). The three distinct Type II subtypes (Chylinski et al. 2014) each contain (1) three Cas proteins (Cas1, Cas2, and Cas9), (2) a *trans*-activating crRNA (tracrRNA) (Deltcheva et al. 2011), and (3) the CRISPR array (Fig. 1A). Interestingly, a fourth Cas protein is found in Type II-A (Csn2) and Type II-B (Cas4) systems but not Type II-C systems (Chylinski et al. 2014). Cas1 and Cas2 are presumed to be essential for adaptation in Type II systems, given their vital role in adaptation in Type I systems (Datsenko et al. 2012; Yosef et al. 2012; Diez-Villasenor et al. 2013; Nunez et al. 2014). Genetic studies (*cas* gene disruptions) in *Streptococcus thermophilus* suggest a specific requirement for Csn2 in Type II-A adaptation (Barrangou et al. 2007). Expanded CRISPR loci were not observed in a *csn2* disruption strain challenged by lytic phage infection (Barrangou et al. 2007). crRNA production (Carte et al. 2014) and invader defense (Barrangou et al. 2007) were unaffected in the *csn2* disruption strain. Cas9 (common to Type II systems) has been found to function in crRNA biogenesis and accumulation (Deltcheva et al. 2011; Carte et al. 2014) and invader defense (Barrangou et al. 2007; Garneau et al. 2010); however, the potential role of Cas9 in adaptation has not been examined.

© 2015 Wei et al. This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genesdev.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

[**Keywords:** CRISPR; adaptation; Cas9; PAM; *Streptococcus thermophilus*]  
**Corresponding authors:** [mterns@bmb.uga.edu](mailto:mterns@bmb.uga.edu), [rterns@bmb.uga.edu](mailto:rterns@bmb.uga.edu)  
Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.257550.114>.



**Figure 1.** Cas1, Cas2, and Csn2 are critical for adaptation. (A) Illustration of CRISPR1 module and adaptation. (Top) The *S. thermophilus* DGCC7710 CRISPR1 module encodes four Cas proteins: Cas1, Cas2, Csn2, and Cas9. The tracrRNA is encoded between Cas9 and Cas1. The CRISPR leader sequence (gray) is followed by 32 repeat (R, black)–spacer (S, colored) units (only a few of which are shown for simplicity). The locations of primers used in PCR for detection of new spacer acquisition are indicated by red arrows. (Bottom) The product of acquisition of a novel spacer (asterisk; purple) and an associated repeat is illustrated. (B) Analysis of spacer acquisition in wild-type (left) and *cas1/cas2/csn2* deletion (right) strains expressing combinations of Cas1, Cas2, and Csn2 proteins from plasmids. The leader-proximal region of CRISPR1 was PCR-amplified with primers indicated in A. Plasmid expression of individual proteins is indicated with “+” or “–” signs. The PCR product corresponding to addition of one repeat–spacer unit is indicated with an asterisk. Sizes of DNA standards (M) are indicated. Data representative of multiple experiments are shown.

As the effector nuclease of Type II CRISPR–Cas systems, Cas9 (guided by a crRNA/tracrRNA duplex) cuts opposing strands of complementary invading DNA using two nuclease domains (RuvC and HNH) (Garneau et al. 2010; Gasiunas et al. 2012; Jinek et al. 2012). The nuclease activity of the Cas9/guide RNA complex has been adapted as a powerful genome-editing tool in a variety of cell types and organisms (for review, see Terns and Terns 2014). Mutation of the nuclease domains results in a catalytically defective form of Cas9 (dCas9) that has been applied to control gene expression as an RNA-guided DNA-binding protein (Terns and Terns 2014).

In this study, we examined adaptation by a Type II-A CRISPR–Cas system in *S. thermophilus*. We expressed increased levels of Cas1, Cas2, and Csn2 to attain levels of adaptation that were detectable without selection in populations of cells. We tested the role of all four Type II-A Cas proteins in adaptation and unexpectedly found that Cas9 (the effector nuclease) is also required for adaptation. The nuclease activity of Cas9 is not required for adaptation, and, in the absence of nuclease destruction of the targets of acquired sequences, we found that the host genome is targeted without discrimination (i.e., equivalently to an invader) by the CRISPR–Cas system.

## Results and Discussion

### *Cas1, Cas2, and Csn2 are required for adaptation*

Adaptation (illustrated in Fig. 1A) is rarely detected within prokaryotic populations under laboratory conditions

(Barrangou et al. 2007; Deveau et al. 2008; Garneau et al. 2010). We increased the frequency of adaptation by the Type II-A CRISPR–Cas system (CRISPR1) in *S. thermophilus* by increasing levels of Cas1, Cas2, and Csn2 (three proteins hypothesized to mediate adaptation). Adaptation events within the *S. thermophilus* population at CRISPR1 can be monitored by PCR amplification of the leader-proximal region (Fig. 1B, with primers at red arrows in A). Expansion of CRISPR1 (increase in the size of the PCR product by the unit length of the added spacer and repeat noted with asterisks in Fig. 1B) was observed in a detectable fraction of the population of the wild-type strain containing the pCas1/Cas2/Csn2 plasmid but not an empty plasmid (Fig. 1B, lanes 1,2), indicating that increasing expression of Cas1, Cas2, and Csn2 increases adaptation frequency. To assess whether all three proteins are required to observe adaptation, we systematically eliminated each one (Fig. 1B, lanes 3–5). CRISPR expansion was observed only when all three Cas proteins were expressed (Fig. 1B). Similar results were obtained for expression of the various combinations of Cas proteins in an *S. thermophilus* strain lacking endogenous *cas1*, *cas2*, and *csn2* genes (Fig. 1B, right panel).


These results are the first direct genetic evidence indicating that Cas1, Cas2, and Csn2 each functions in CRISPR adaptation in Type II systems. Recent structural and biochemical studies on *E. coli* Type I-E system components suggest that Cas1 and Cas2 form an integrase-type complex that uses the nuclease active site of Cas1 to carry out spacer integration at CRISPRs (Datsenko et al. 2012; Yosef et al. 2012; Nunez et al. 2014). Csn2 proteins purified from diverse organisms form tetrameric ring-like structures that encircle and bind dsDNA, but no relevant enzymatic activities have yet been identified (Nam et al. 2011; van der Oost et al. 2014). Sequences at the junction of the leader and first repeat of the CRISPR direct the integration of new spacers in *S. thermophilus* CRISPR1 (Wei et al. 2015). The Cas1/Cas2 complex (possibly in association with Csn2) may recognize the leader/repeat junction sequence element to mediate specific integration into CRISPRs at the leader end.

### *Cas9 is required for adaptation*

Surprisingly, we also found that Cas9 plays a role in adaptation in the *S. thermophilus* Type II CRISPR–Cas system. Cas9 was previously found to be the nuclease responsible for invader DNA cleavage in Type II systems and was not expected to play a role in adaptation (Barrangou et al. 2007; Gasiunas et al. 2012; Jinek et al. 2012). Previous studies examined adaptation by methods that required the invader nuclease function of Cas9 (e.g., survival of lytic phage or cleavage of exogenous plasmid) (Barrangou et al. 2007; Deveau et al. 2008; Garneau et al. 2010; Lopez-Sanchez et al. 2012; Paez-Espino et al. 2013) and therefore could not examine adaptation in the absence of Cas9. However, the assay used in this study (detection of adaptation by PCR amplification of the CRISPR locus in cell populations) does not require active defense.

We deleted *cas9* from the genome and, surprisingly, found that the adaptation observed with Cas1/Cas2/Csn2 expression (Fig. 2C, lane 2) was lost in the absence of Cas9 (Fig. 2C, lane 4). Adaptation was rescued by expression of Cas9 from a plasmid (with native promoter) (Fig. 2C, lane 5). Elimination and restoration of Cas9 protein expression

Wei et al.



**Figure 2.** Lack of adaptation in the absence of Cas9 protein and more extensive adaptation in the absence of Cas9 nuclease activity. (A) Cas9 protein levels in *S. thermophilus* wild-type (WT) and *cas9* deletion ( $\Delta cas9$ ) strains expressing Cas1/Cas2/Csn2 and Cas9 proteins from plasmids. Cas9 was detected via Western blot using polyclonal antibodies. Plasmid expression of proteins is indicated with “+” or “-” signs. (B) The sensitivity of strains expressing functional Cas9 (middle) or nuclease-defective Cas9 (right) to lytic phage 2972 relative to a strain lacking Cas9 (left; control) measured as efficiency of plaquing. (C) Analysis of spacer acquisition in wild-type and *cas9* deletion ( $\Delta cas9$ ) strains expressing Cas1/Cas2/Csn2 and Cas9 proteins from plasmids. The leader-proximal region of CRISPR1 was PCR-amplified with primers indicated in Figure 1A. Plasmid expression of proteins is indicated with “+” or “-” signs. PCR products corresponding to addition of one or multiple repeat-spacer units are indicated with an asterisk or bracket, respectively. Sizes of DNA standards (M) are indicated. Data representative of multiple experiments are shown. Noncontiguous lanes from the same gel are separated by a dashed line. (D) Percentages of spacers derived from the plasmid (yellow) and genome (blue) in strains expressing wild-type Cas9 (left; wild-type *S. thermophilus* cells expressing Cas1/Cas2/Csn2) (Fig. 1B, lane 2) or dCas9 (right; *cas9* deletion strain expressing dCas9 and Cas1/Cas2/Csn2) (C, lane 10). See Supplemental Tables S1 and S4 for details. One spacer matched the *cas1* gene, which is present both on the plasmid and in the genome and was arbitrarily assigned to the plasmid.

in the deletion and plasmid rescue strains, respectively, was confirmed by Western analysis (Fig. 2A). These results indicate that, surprisingly, Cas9 is important for acquisition of invader sequences as well as invader destruction.

Both adaptation and invader destruction depend on PAMs in Type I and Type II CRISPR–Cas systems (Mojica et al. 2009; Shah et al. 2013; Heler et al. 2014). PAMs are important for initial protospacer selection in adaptation (in which the motifs are more specifically termed SAMs [spacer acquisition motifs]) and subsequent recognition of that protospacer sequence as the target for invader

destruction (in which the motifs are more specifically termed TIMs [target interference motifs]) (Shah et al. 2013). The PAM sequence required by a CRISPR–Cas system is not found in its CRISPR repeat sequence, thereby ensuring that when a sequence is incorporated into a CRISPR, the copy in the CRISPR of the host genome is not targeted for cleavage. Evidence indicates that the C-terminal domain of Cas9 interacts with the TIM in the context of the crRNA-containing invader targeting complex for Type II systems (Anders et al. 2014; Nishimasu et al. 2014; Sternberg et al. 2014). Our findings suggest Cas9 as a likely SAM recognition factor in adaptation, providing the critical link that ensures that sequences selected for acquisition will be recognized and effectively silenced by the effector complex.

#### *The RuvC- and HNH-based nuclease activities of Cas9 are not required for adaptation*

In invader defense, Cas9 uses RuvC and HNH domains for target DNA cleavage (Gasiunas et al. 2012; Jinek et al. 2012). Adaptation conceivably also involves dsDNA cleavages (to obtain the protospacer fragment from the invader and open the CRISPR for integration of the new spacer). To assess whether the ability to cleave DNA is important for Cas9 function in adaptation, we introduced nuclease domain mutations (Gasiunas et al. 2012; Jinek et al. 2012; Nishimasu et al. 2014) into Cas9 within pCas1/Cas2/Csn2/Cas9 (and refer to the mutant Cas9<sup>D9A/H599A</sup> as dCas9 for catalytically defective Cas9) and expressed the construct in the *S. thermophilus cas9* deletion strain. We confirmed that the mutant Cas9 protein is expressed (Fig. 2A) and is defective in invader defense: The strain expressing the nuclease mutant fails to resist a *S. thermophilus* lytic phage that is effectively targeted in the presence of wild-type Cas9 (Fig. 2B). However, we found that mutations in the RuvC and HNH domains did not disrupt adaptation (Fig. 2C, lanes 10–12), indicating that the nuclease activity of Cas9 is not required for adaptation.

Moreover, when target destruction was blocked by elimination of Cas9 nuclease activity, spacer accumulation increased significantly. PCR analysis of the cultures indicates that almost all of the cells in the population have acquired at least one spacer. Very little of the product corresponding to the original unadapted CRISPR locus is observed in these cultures (Fig. 2C, lanes 10–12 are examples of three independent cultures). Furthermore, many cells acquired two, three, or more spacers, evidenced by the PCR products of increasing repeat-spacer unit size (Fig. 2C, lanes 10–12). In the presence of functional Cas9, any individual that has acquired a spacer targeting the plasmid (or the genome) is eventually expected to be lost from the population due to chloramphenicol selection against loss of the plasmid (or lethality of genome targeting). In the presence of nuclease-defective Cas9, however, individuals that have undergone adaptation can survive and acquire additional spacers. It is also possible that in the absence of nuclease activity, Cas9 becomes more available for its role in adaptation.

#### *CRISPR1 acquires sequences from the genome as well as invader plasmid*

We examined the origin and context of the new spacers that we had initially observed in the wild-type *S. thermo-*

*philus* cells expressing Cas1/Cas2/Csn2 (in the presence of functional Cas9 and active defense) (Fig. 1B, lane 2). Of 37 unique spacers, 25 spacers (68%) were directed against the plasmid, and, interestingly, 12 spacers (32%) were from the *S. thermophilus* genome (Fig. 2D; Supplemental Table S1). (One spacer matched the *cas1* gene, which is present both on the plasmid and in the genome and is arbitrarily assigned to the plasmid.) A PAM/SAM sequence is crucial for selection of an invader sequence for CRISPR incorporation (Mojica et al. 2009; Shah et al. 2013; Heler et al. 2014), and, consistently, we found the predicted NNAGAAW PAM sequence (or a previously observed variation of this consensus motif) (Deveau et al. 2008; Garneau et al. 2010; Paez-Espino et al. 2013) present adjacent to each protospacer sequence in the source, whether it was the plasmid or the genome (Supplemental Tables S1, S2).

In our assay, both the genome- and plasmid-derived spacers acquired in the presence of functional Cas9 are expected to be lost from the population over time due to the deleterious effect of targeting either source. While we observed a significant extent of acquisition of spacers from the host genome, spacers from the genome are nonetheless distinctly underrepresented relative to those from the plasmid (Fig. 1B, lane 2; Supplemental Table S1). The *S. thermophilus* genome ( $\sim 1.8 \times 10^6$  bp) represents  $\sim 100$  times the DNA content of the plasmid within the cell ( $\sim 1.8 \times 10^4$  bp when adjusted for plasmid copy number of approximately three) (Kok et al. 1984). However, at the time point examined, more spacers found in the population are from the plasmid (68%) than from the genome (32%), suggesting active selection of plasmid-derived spacers. Alternatively, the underrepresentation of spacers from the genome could reflect a greater penalty for targeting the host genome relative to an antibiotic-selected plasmid.

Notably, among the 25 plasmid-derived spacers, only one (4%) matched the *cas1/cas2/csn2*-coding region despite the fact that these genes comprise 37% of the plasmid sequence and contain 35% of the consensus (NNAGAAW) PAMs in the plasmid (Fig. 3, left panel). The underrepresentation of *cas1/cas2/csn2*-matching spacers could reflect specific avoidance of the *cas* genes in the process of adaptation or the detrimental effect of genome-matching spacers in an active CRISPR–Cas


system (as spacers matching the *cas1/cas2/csn2*-coding region of the plasmid would also target the endogenous *cas1/cas2/csn2* genes present in the genome). To determine whether the presence of genome copies impacts the abundance of spacers against the *cas* genes on the plasmid, we examined the sequences of spacers acquired in the strain lacking the *cas1/cas2/csn2* gene targets within the genome (*cas1/cas2/csn2* deletion strain) (Fig. 1B, lane 8). We found that the *cas1/cas2/csn2* genes were targeted without bias in the absence of the genome copies: Ten (42%) of 24 plasmid spacers matched the *cas1/cas2/csn2* genes (Fig. 3, right panel; Supplemental Table S3). The results provide further support that spacers targeting the genome (as opposed to the plasmid only) are more effectively lost from the population.

#### *Elimination of Cas9 nuclease activity reveals extensive, unbiased acquisition of spacers from the genome*

Our findings indicate that spacers are acquired from the genome and lost from the population due to subsequent CRISPR–Cas targeting of the genome. To better determine the extent of genome spacer acquisition, we examined adaptation in the absence of target destruction. We sequenced 48 spacers from the *cas9* deletion strain expressing dCas9 and Cas1/Cas2/Csn2 (Fig. 2C, lane 10). Remarkably, we found that, in the absence of defense, the overwhelming majority of spacers were derived from the genome: Forty-six of the 48 spacers (96%) were derived from the *S. thermophilus* genome, and two spacers (4%) originated from the plasmid (Fig. 2D, right; Supplemental Table S4). The distribution correlates well with the relative DNA content of the cell (99% genome and 1% plasmid), indicating that the host genome is targeted for spacer acquisition equivalently to the plasmid and that there is no significant bias for invader DNA in CRISPR–Cas adaptation by this system. PAM distribution in the presence of dCas9 is similar to that in the presence of wild-type Cas9 (Supplemental Table S5).

Self-targeting spacers are rarely observed at steady state in organisms with functioning CRISPR–Cas systems: Computational analysis of 23,550 spacers from 330 organisms found that 0.4% of all sequenced spacers were self-targeting (Stern et al. 2010). Moreover, in a study of long-term lytic phage infection of *S. thermophilus*, only 0.04% of acquired spacers observed were found to match the host genome (Paez-Espino et al. 2013). Some evidence indicates that invader sequences are actively selected and/or that genome sequences are actively avoided by CRISPR–Cas adaptation systems. In a Type I-E system in *E. coli*, spacers targeting plasmids were found to significantly outnumber genome-derived spacers even in the absence of CRISPR–Cas defense (Yosef et al. 2012; Diez-Villasenor et al. 2013). However, our analysis of a Type II-A system in *S. thermophilus* indicates that spacers are acquired from the genome more frequently than invader nucleic acid (in proportion to the relative cellular DNA content of each) and are eliminated from the population by subsequent CRISPR–Cas system targeting.

Our analysis of adaptation in *S. thermophilus* in the absence of defense unmasked a higher rate of ongoing adaptation (Fig. 2C, lanes 10–12) as well as extensive and unbiased genome sampling in this organism (Supplemental Table S4). Our results indicate that extensive acquisition of genome sequences occurs within populations and



**Figure 3.** Distribution of pCas1/Cas2/Csn2 plasmid protospacers in wild-type (left) and *cas1/cas2/csn2* deletion strains (right). Protospacer positions and orientations (designated with green and red arrows) are marked on the pCas1/Cas2/Csn2 plasmid map. Cas1-, Cas2-, and Csn2-coding regions are labeled with open arrows.

Wei et al.

is normally undetected due to the lethal consequence of the event. Our findings provide strong evidence that some CRISPR–Cas systems provide prokaryotes with a bet-hedging strategy to survive nucleic acid invaders—available DNA is randomly incorporated into the CRISPR locus, and the individuals that acquire genome targeting spacers die, but those that acquire invader targeting spacers gain a fitness advantage that can ensure survival. The lack of discrimination in spacer acquisition may illuminate the need for the low rate of adaptation generally observed among prokaryotic populations: avoiding loss of great numbers of the population due to acquisition of self-targeting spacers while providing for a rate of acquisition sufficient to ensure survival upon encountering a damaging invader.

## Materials and methods

### Strains and plasmids

*S. thermophilus* DGCC7710 was kindly provided by Dr. Sylvain Moineau. The *cas9* deletion and *cas1/cas2/csn2* deletion strains were constructed using methods developed by Renye and Somkuti (2009) using plasmid pINTRS. Sequences of the CRISPR locus and deleted regions are shown in that Supplemental Material. *S. thermophilus* was maintained in M17 medium (Oxoid) supplemented with 0.5% lactose (LM17). *S. thermophilus* cultures were grown overnight at 37° and during the day (8 h) at 42°. *E. coli* Top10 (grown in Luria broth) was used for cloning and plasmid maintenance. For strains harboring pWAR228-derived plasmids (kindly provided by Dr. Michael Federle), chloramphenicol was supplemented at 10 µg/mL for *E. coli*, at 2 µg/mL in LM17 broth, and at 5 µg/mL in LM17 plates (1% agar) for *S. thermophilus*. Strains and plasmids used in this study are listed in Supplemental Table S6.

### DNA manipulation

Standard protocols were used for cloning. Phusion polymerase, restriction enzymes, and T4 DNA ligase were from New England Biolabs. Taq polymerase with Crimson Taq buffer (New England Biolabs) was used for colony PCR. Zymoclean gel DNA recovery kit (Zymo Research) was used for gel extraction. QIAprep Spin miniprep kit and QIAfilter plasmid midi kit (Qiagen) were used for plasmid preparations. DNA Clean and Concentrator-5 (Zymo Research) was used for concentrating plasmids.

### Construction of plasmids

Plasmid pWAR228 was used as the backbone for plasmid constructions. The *Ppgm* promoter was PCR-amplified from plasmid pTRK882 (kindly provided by Dr. Todd Klaenhammer) (Duong et al. 2011). The *Cas1/Cas2/Csn2*-coding region adjacent to CRISPR1 was PCR-amplified from the *S. thermophilus* genome and linked to the *Ppgm* promoter via overlap PCR. The final PCR product was assembled onto pWAR228 to yield plasmid pCas1/Cas2/Csn2 via restriction digestion (XhoI and NotI sites) and ligation. Inverse PCR was used to delete each of the three *cas* genes on pCas1/Cas2/Csn2. To construct pCas1/Cas2/Csn2/Cas9, the *Cas9* promoter and coding region were PCR-amplified from the *S. thermophilus* genome and assembled onto pCas1/Cas2/Csn2 via restriction digestion (using a XhoI site) and ligation to yield pCas1/Cas2/Csn2/Cas9. Active sites of *Cas9* were mutagenized (D9A and H599A) via QuikChange PCR using pCas1/Cas2/Csn2/Cas9 as the template. Plasmid constructions were confirmed by sequencing and transformed into *S. thermophilus* via electroporation (Garneau et al. 2010). Oligos used for cloning are listed in Supplemental Table S7.

### Population-based adaptation assay and spacer sequence analysis

*S. thermophilus* cells harboring the indicated plasmids were grown in LM17 supplemented with 2 µg/mL chloramphenicol for 16 h. Cells from

each strain were pelleted, resuspended in water by vortexing, and used as PCR templates. Primers matching the leader and the first spacer of CRISPR1 (Supplemental Table S7) were used for PCR amplification of CRISPR1. PCR products were run on 2% TAE-agarose gels, stained with ethidium bromide, and examined under UV light to assess CRISPR expansion. Gel bands were excised, purified, cloned into Topo vector using the Zero Blunt TOPO PCR cloning kit (Life Technology), and sequenced (Eurofins Genomics).

### Western blotting

Wild-type *S. thermophilus* or *S. thermophilus* strains harboring the indicated plasmids were grown overnight. Cells were pelleted and lysed with a Mini-Beadbeater (Biospec Products). Thirty micrograms of total protein from each lysate was separated on a 10% SDS-PAGE gel and blotted onto a nitrocellulose membrane (Bio-Rad). *Cas9* protein was detected using polyclonal chicken antibodies raised against *Cas9* and HRP-conjugated donkey anti-chicken IgY (Gallus Immumotech).

### Phage defense assay

An *S. thermophilus cas9* deletion strain harboring pCas1/Cas2/Csn2/Cas9 was infected with lytic phage 2972. A surviving strain, which was confirmed to have obtained a phage-matching spacer in CRISPR1 (protospacer, AAATCAGTTTTTGTTCAGAAACTTGTCT; PAM, TTAGAAA), was allowed to lose the plasmid through passages on growth medium without antibiotics. The resulting strain (without the plasmid) was back-transformed with pCas1/Cas2/Csn2, pCas1/Cas2/Csn2/Cas9, or pCas1/Cas2/Csn2/dCas9 and tested for sensitivity to lytic phage 2972 as previously described (Barrangou et al. 2007).

## Acknowledgments

We thank members of the Terns laboratory and Claiborne Glover for helpful discussions, and Anthony Schmalstig, Xinfu Zhang, and Erin Hollander for *S. thermophilus* strain construction. We also thank Rodolphe Barrangou, Sylvain Moineau, Todd Klaenhammer, Michael Federle, John Renye, and George Somkuti for generously providing strains, phage, and plasmids. This study is supported by National Institutes of Health (NIH) grant RO1 GM099876 to M.P.T. and R.M.T. Y.W. is supported by the National Institute of General Medical Sciences of the NIH under award number F32GM108263.

## References

- Anders C, Niewoehner O, Duerst A, Jinek M. 2014. Structural basis of PAM-dependent target DNA recognition by the *Cas9* endonuclease. *Nature* **513**: 569–573.
- Barrangou R, Marraffini LA. 2014. CRISPR–Cas systems: prokaryotes upgrade to adaptive immunity. *Mol Cell* **54**: 234–244.
- Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. 2007. CRISPR provides acquired resistance against viruses in prokaryotes. *Science* **315**: 1709–1712.
- Carte J, Christopher RT, Smith JT, Olson S, Barrangou R, Moineau S, Glover CV 3rd, Graveley BR, Terns RM, Terns MP. 2014. The three major types of CRISPR–Cas systems function independently in CRISPR RNA biogenesis in *Streptococcus thermophilus*. *Mol Microbiol* **93**: 98–112.
- Chylinski K, Makarova KS, Charpentier E, Koonin EV. 2014. Classification and evolution of type II CRISPR–Cas systems. *Nucleic Acids Res* **42**: 6091–6105.
- Datsenko KA, Pougach K, Tikhonov A, Wanner BL, Severinov K, Semenova E. 2012. Molecular memory of prior infections activates the CRISPR/Cas adaptive bacterial immunity system. *Nat Commun* **3**: 945.
- Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, Eckert MR, Vogel J, Charpentier E. 2011. CRISPR RNA maturation by *trans*-encoded small RNA and host factor RNase III. *Nature* **471**: 602–607.
- Deveau H, Barrangou R, Garneau JE, Labonte J, Fremaux C, Boyaval P, Romero DA, Horvath P, Moineau S. 2008. Phage response to CRISPR-encoded resistance in *Streptococcus thermophilus*. *J Bacteriol* **190**: 1390–1400.

- Diez-Villasenor C, Guzman NM, Almendros C, Garcia-Martinez J, Mojica FJ. 2013. CRISPR-spacer integration reporter plasmids reveal distinct genuine acquisition specificities among CRISPR-Cas I-E variants of *Escherichia coli*. *RNA Biol* **10**: 792–802.
- Duong T, Miller MJ, Barrangou R, Azcarate-Peril MA, Klaenhammer TR. 2011. Construction of vectors for inducible and constitutive gene expression in *Lactobacillus*. *Microb Biotechnol* **4**: 357–367.
- Erdmann S, Garrett RA. 2012. Selective and hyperactive uptake of foreign DNA by adaptive immune systems of an archaeon via two distinct mechanisms. *Mol Microbiol* **85**: 1044–1056.
- Garneau JE, Dupuis ME, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, Horvath P, Magadan AH, Moineau S. 2010. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. *Nature* **468**: 67–71.
- Gasiunas G, Barrangou R, Horvath P, Siksnys V. 2012. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proc Natl Acad Sci* **109**: E2579–E2586.
- Haft DH, Selengut J, Mongodin EF, Nelson KE. 2005. A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes. *PLoS Comput Biol* **1**: e60.
- Heler R, Marraffini LA, Bikard D. 2014. Adapting to new threats: the generation of memory by CRISPR-Cas immune systems. *Mol Microbiol* **93**: 1–9.
- Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA. 2013. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. *Nat Biotechnol* **31**: 233–239.
- Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* **337**: 816–821.
- Kok J, van der Vossen JM, Venema G. 1984. Construction of plasmid cloning vectors for lactic streptococci which also replicate in *Bacillus subtilis* and *Escherichia coli*. *Appl Environ Microbiol* **48**: 726–731.
- Li M, Wang R, Xiang H. 2014. *Haloarcula hispanica* CRISPR authenticates PAM of a target sequence to prime discriminative adaptation. *Nucleic Acids Res* **42**: 7226–7235.
- Lopez-Sanchez MJ, Sauvage E, Da Cunha V, Clermont D, Ratsima Hariniaina E, Gonzalez-Zorn B, Poyart C, Rosinski-Chupin I, Glaser P. 2012. The highly dynamic CRISPR1 system of *Streptococcus agalactiae* controls the diversity of its mobilome. *Mol Microbiol* **85**: 1057–1071.
- Makarova KS, Haft DH, Barrangou R, Brouns SJ, Charpentier E, Horvath P, Moineau S, Mojica FJ, Wolf YI, Yakunin AF, et al. 2011. Evolution and classification of the CRISPR-Cas systems. *Nat Rev Microbiol* **9**: 467–477.
- Mojica FJ, Diez-Villasenor C, Garcia-Martinez J, Almendros C. 2009. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. *Microbiology* **155**: 733–740.
- Nam KH, Kurinov I, Ke A. 2011. Crystal structure of clustered regularly interspaced short palindromic repeats (CRISPR)-associated Csn2 protein revealed Ca<sup>2+</sup>-dependent double-stranded DNA binding activity. *J Biol Chem* **286**: 30759–30768.
- Nishimasu H, Ran FA, Hsu PD, Konermann S, Shehata SI, Dohmae N, Ishitani R, Zhang F, Nureki O. 2014. Crystal structure of Cas9 in complex with guide RNA and target DNA. *Cell* **156**: 935–949.
- Nunez JK, Kranzusch PJ, Noeske J, Wright AV, Davies CW, Doudna JA. 2014. Cas1-Cas2 complex formation mediates spacer acquisition during CRISPR-Cas adaptive immunity. *Nat Struct Mol Biol* **21**: 528–534.
- Paez-Espino D, Morovic W, Sun CL, Thomas BC, Ueda K, Stahl B, Barrangou R, Banfield JF. 2013. Strong bias in the bacterial CRISPR elements that confer immunity to phage. *Nat Commun* **4**: 1430.
- Renye JA Jr, Somkuti GA. 2009. Insertion of a heterologous gene construct into a non-functional ORF of the *Streptococcus thermophilus* chromosome. *Biotechnol Lett* **31**: 759–764.
- Shah SA, Erdmann S, Mojica FJ, Garrett RA. 2013. Protospacer recognition motifs: mixed identities and functional diversity. *RNA Biol* **10**: 891–899.
- Stern A, Keren L, Wurtzel O, Amitai G, Sorek R. 2010. Self-targeting by CRISPR: gene regulation or autoimmunity? *Trends Genet* **26**: 335–340.
- Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA. 2014. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. *Nature* **507**: 62–67.
- Swarts DC, Mosterd C, van Passel MW, Brouns SJ. 2012. CRISPR interference directs strand specific spacer acquisition. *PLoS ONE* **7**: e35888.
- Terns MP, Terns RM. 2011. CRISPR-based adaptive immune systems. *Curr Opin Microbiol* **14**: 321–327.
- Terns RM, Terns MP. 2014. CRISPR-based technologies: prokaryotic defense weapons repurposed. *Trends Gen* **30**: 111–118.
- van der Oost J, Westra ER, Jackson RN, Wiedenheft B. 2014. Unravelling the structural and mechanistic basis of CRISPR-Cas systems. *Nat Rev Microbiol* **12**: 479–492.
- Wei Y, Chesne MT, Terns RM, Terns MP. 2015. Sequences spanning the leader-repeat junction mediate CRISPR adaptation to phage in *Streptococcus thermophilus*. *Nucleic Acids Res* doi: 10.1093/nar/gku1407.
- Yosef I, Goren MG, Qimron U. 2012. Proteins and DNA elements essential for the CRISPR adaptation process in *Escherichia coli*. *Nucleic Acids Res* **40**: 5569–5576.



## Cas9 function and host genome sampling in Type II-A CRISPR–Cas adaptation

Yunzhou Wei, Rebecca M. Terns and Michael P. Terns

*Genes Dev.* 2015, **29**:

Access the most recent version at doi:[10.1101/gad.257550.114](https://doi.org/10.1101/gad.257550.114)

---


**Supplemental Material** <http://genesdev.cshlp.org/content/suppl/2015/02/17/29.4.356.DC1>

**References** This article cites 36 articles, 6 of which can be accessed free at:  
<http://genesdev.cshlp.org/content/29/4/356.full.html#ref-list-1>

**Creative Commons License** This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genesdev.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

**Email Alerting Service** Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

---

An advertisement for EXIQON. On the left, there is a photograph of a small, clear plastic vial with a blue cap, containing a yellow liquid. To the right of the vial is a dark grey rectangular box with white text. The text reads: 'Biofluids too dilute to detect microRNAs? See what to do.' In the top right corner of this box, the word 'EXIQON' is written in a bold, white, sans-serif font.

Biofluids too dilute to detect microRNAs? See what to do. EXIQON